Last reviewed · How we verify
Candesartan+HCTZ - Phase 1
Candesartan blocks angiotensin II receptors to lower blood pressure, while HCTZ is a thiazide diuretic that reduces fluid volume and sodium reabsorption.
Candesartan blocks angiotensin II receptors to lower blood pressure, while HCTZ is a thiazide diuretic that reduces fluid volume and sodium reabsorption. Used for Hypertension.
At a glance
| Generic name | Candesartan+HCTZ - Phase 1 |
|---|---|
| Sponsor | Novartis |
| Drug class | Angiotensin II receptor blocker + thiazide diuretic combination |
| Target | AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Candesartan is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from binding to AT1 receptors on blood vessels and the heart, causing vasodilation and reduced blood pressure. Hydrochlorothiazide (HCTZ) is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urine output and reducing blood volume. The combination provides complementary antihypertensive effects through different mechanisms.
Approved indications
- Hypertension
Common side effects
- Dizziness
- Fatigue
- Hyperuricemia
- Hypokalemia
- Headache
- Cough
Key clinical trials
- Recurrent Stroke Prevention Clinical Outcome Study (PHASE4)
- Safety and Efficacy of Aliskiren + Hydrochlorothiazide (± Amlodipine 5 mg) in Patients With Moderate Hypertension (PHASE3)
- Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo (PHASE3)
- Candesartan Effect in Second Stage Arterial Hypertension (PHASE4)
- Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Candesartan+HCTZ - Phase 1 CI brief — competitive landscape report
- Candesartan+HCTZ - Phase 1 updates RSS · CI watch RSS
- Novartis portfolio CI